{"id":56209,"date":"2026-02-20T12:09:31","date_gmt":"2026-02-20T17:09:31","guid":{"rendered":"https:\/\/www.rxbriefcase.com\/?p=56209"},"modified":"2026-02-20T12:09:33","modified_gmt":"2026-02-20T17:09:33","slug":"safe-medication-use-for-older-adults-with-cvd","status":"publish","type":"post","link":"https:\/\/www.rxbriefcase.com\/fr\/safe-medication-use-for-older-adults-with-cvd\/","title":{"rendered":"Safe Medication Use for Older Adults with CVD"},"content":{"rendered":"

Cardiovascular disease (CVD) remains the global leader in mortality, claiming an estimated 17.9 million lives<\/strong><\/a> annually\u2014nearly twice as many as cancer. As our population ages, the stakes only get higher. By 2030, 20% of the world\u2019s population will be 65 or older, and for those over 70, the prevalence of CVD jumps to a staggering 70%<\/strong>.<\/p>\n\n\n\n

Managing heart health in older adults isn’t just about following standard guidelines; it\u2019s about navigating a unique set of physiological and pharmacological challenges.<\/p>\n\n\n\n

The challenge: scarcity of evidence<\/strong><\/p>\n\n\n\n

One of the biggest hurdles in cardiovascular care for older populations is the “evidence gap”. Patients aged 75 and older are frequently underrepresented in major clinical trials<\/a>. Because they often have complex comorbidities, frailty, or significant disabilities, they are excluded from the very studies that dictate our clinical recommendations.<\/p>\n\n\n\n

This leaves clinicians in a delicate position: we know CVD is partially preventable, yet we must manage it in a population where age-related changes to organ systems make every pharmacological intervention a higher risk.<\/p>\n\n\n\n

Assessing risk<\/strong><\/h3>\n\n\n\n

In younger patients, risk assessment is often straightforward. In older adults, we need tools that account for the nuances of aging. Here are some of the key algorithms currently used to help quantify risk:<\/p>\n\n\n\n